1. Home
  2. AYTU vs EONR Comparison

AYTU vs EONR Comparison

Compare AYTU & EONR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • EONR
  • Stock Information
  • Founded
  • AYTU N/A
  • EONR 2020
  • Country
  • AYTU United States
  • EONR United States
  • Employees
  • AYTU N/A
  • EONR N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • EONR
  • Sector
  • AYTU Health Care
  • EONR
  • Exchange
  • AYTU Nasdaq
  • EONR NYSE
  • Market Cap
  • AYTU 9.8M
  • EONR 10.7M
  • IPO Year
  • AYTU N/A
  • EONR N/A
  • Fundamental
  • Price
  • AYTU $1.38
  • EONR $0.59
  • Analyst Decision
  • AYTU
  • EONR Strong Buy
  • Analyst Count
  • AYTU 0
  • EONR 1
  • Target Price
  • AYTU N/A
  • EONR $4.50
  • AVG Volume (30 Days)
  • AYTU 37.2K
  • EONR 144.3K
  • Earning Date
  • AYTU 02-12-2025
  • EONR 02-15-2025
  • Dividend Yield
  • AYTU N/A
  • EONR N/A
  • EPS Growth
  • AYTU N/A
  • EONR N/A
  • EPS
  • AYTU N/A
  • EONR N/A
  • Revenue
  • AYTU $79,759,000.00
  • EONR $21,714,016.00
  • Revenue This Year
  • AYTU N/A
  • EONR N/A
  • Revenue Next Year
  • AYTU N/A
  • EONR N/A
  • P/E Ratio
  • AYTU N/A
  • EONR N/A
  • Revenue Growth
  • AYTU N/A
  • EONR N/A
  • 52 Week Low
  • AYTU $1.30
  • EONR $0.51
  • 52 Week High
  • AYTU $3.45
  • EONR $6.00
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 33.90
  • EONR N/A
  • Support Level
  • AYTU $1.30
  • EONR N/A
  • Resistance Level
  • AYTU $1.47
  • EONR N/A
  • Average True Range (ATR)
  • AYTU 0.12
  • EONR 0.00
  • MACD
  • AYTU -0.01
  • EONR 0.00
  • Stochastic Oscillator
  • AYTU 17.78
  • EONR 0.00

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About EONR EON RESOURCES INC

EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.

Share on Social Networks: